Key facts
- This page summarizes Jonathan Mark Hopper's Form 4 filing for Vericel Corp (VCEL).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 13 Feb 2024, 16:06.
Jonathan Mark Hopper - 12 Feb 2024 Form 4 Insider Report for Vericel Corp (VCEL)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- VCEL
- Reported as of
- 12 Feb 2024
- Net transaction value
- -$36,750
- SEC form
- 4
- Accepted by SEC
- 13 Feb 2024, 16:06:01 UTC
- Prior SEC filing
- 22 Nov 2023
- Next SEC filing
- 22 Feb 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Sean Flynn, as Attorney-in-Fact for Jonathan Hopper
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jonathan Mark Hopper filed Form 4 for Vericel Corp (VCEL) on 13 Feb 2024.
Change
- Previous filing in this sequence was filed on 22 Nov 2023.
- Current net transaction value: -$36,750.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VCEL
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +1,625
- Change %
- +3.1%
- Price
- $0.000000
- Shares after
- 54,759
- Date
- 12 Feb 2024
- Ownership
- Direct
- Footnotes
- F1, F2
VCEL
transaction
Common Stock
Tax liability
- Transaction value
- $36,750
- Shares
- -775
- Change %
- -1.4%
- Price
- $47.42
- Shares after
- 53,984
- Date
- 12 Feb 2024
- Ownership
- Direct
- Footnotes
- F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
VCEL
transaction
Derivative
Restricted Stock Unit
Options Exercise
- Transaction value
- Shares
- +1,625
- Change %
- Price
- Shares after
- 0
- Date
- 12 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,625
- Exercise price
- Footnotes
- F1, F4, F5, F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 6 footnotes
Footnote F1
The shares of common stock were acquired by the Reporting Person as a result of the vesting of the Restricted Stock Units (RSUs) granted to the Reporting Person on February 11, 2020.
Footnote F2
These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
Footnote F3
These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs.
Footnote F4
Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.
Footnote F5
No expiration date for this type of award.
Footnote F6
The Fair Market Value of the vested derivative securities is $47.42 per share.